More than one encoding rule for CDR sequences is required to reduce the risk of missing FTO sequences in antibody searches.

This article summarized the latest R&D progress of granisetron hydrochloride, the Mechanism of Action for granisetron hydrochloride, and the drug target R&D trends for granisetron hydrochloride.

Disease-Specific Survival (DSS) refers to deaths caused specifically by a particular disease.

Nature reported on a discovery by AbbVie, the Broad Institute, and Calico Life Sciences. Their research indicates the potential of ABBV-CLS-484, an experimental drug, to act as a PTPN2/N1 phosphatase inhibitor boosting anti-cancer immunity, orally administered.

Milestone survival rate is defined as the survival probability at a given point in time.

This article summarized the latest R&D progress of imiglucerase, the Mechanism of Action for imiglucerase, and the drug target R&D trends for imiglucerase.

Moderna, Inc. reported encouraging preliminary outcomes from the mRNA-1083 Phase 1/2 study, a combination vaccine currently under investigation for its effect against both influenza and COVID-19.

This article summarized the latest R&D progress of infliximab-abda, the Mechanism of Action for infliximab-abda, and the drug target R&D trends for infliximab-abda.

Health-Related Quality of Life (HRQoL) is a significant indicator for assessing the quality of life and health status of patients.

Circular RNA (circRNA) is a type of single-stranded RNA with a closed loop structure, initially found in HDV and plant viruses.

Vedanta Biosciences recently reported the initiation of treatment for the initial participant in the COLLECTiVE202 Phase 2 investigation of VE202.

This article summarized the latest R&D progress of eflornithine hydrochloride, the Mechanism of Action for eflornithine hydrochloride, and the drug target R&D trends for eflornithine hydrochloride.